期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 61, 期 1, 页码 1-14出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2008.12.051
关键词
-
类别
资金
- NIAMS NIH HHS [T32 AR053458, T32 AR053458-03] Funding Source: Medline
Neurofibromatosis type 1 (NF1) is an autosomal dominant, multisystem disorder affecting approximately 1 in 3500 people. significant advances in the understanding of the pathophysiology of NF1 have been made in the last decade. While no medical therapies for NF1 are currently available, trials are ongoing to discover and test medical treatments for the various manifestations of NF1, primarily plexiform neurofibromas, learning disabilities, and optic pathway gliomas. In addition, mutational analysis has become available on a clinical basis and is useful for diagnostic confirmation in individuals who do not fulfill diagnostic criteria or when a prenatal diagnosis is desired. There are several disorders that may share overlapping features with NF1; in 2007, a disorder with cutaneous findings similar to NF1 was described. This paper addresses the dermatologist's role in diagnosis and management of NF1 and describes the variety of cutaneous and extracutaneous findings NF1 to which the dermatologist may be exposed. (J Am Acad Dermatol 2009;61:1-14.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据